Tuesday, March 11, 2014
Friday, March 7, 2014
Wednesday, March 5, 2014
Tuesday, March 4, 2014
It is therefore an apt description for the Ebola clinical trial now underway which is testing the safety and tolerability of SNALP LNP delivery following multiple consecutive daily administrations. This compares to once-weekly and once-a-monthly regimens tested so far. If SNALP LNP comes out positive from this, it would provide great comfort around the safety and tolerability of the industry’s most potent delivery technology for gene knockdown in the liver, in addition to paving the way towards more biodefense applications.
Thursday, February 27, 2014
Tuesday, February 25, 2014
Importantly, the formulation process and chemistry were optimized for mRNA delivery thus generating electron-dense ~80nm particles and easily surpassing >90% encapsulation efficiencies that are thought to be required to pass regulatory CMC muster.
Friday, February 21, 2014
And finally...the ISIS-SMNRx results increase the value of Marina Biotech's CRN chemistry. This chemistry competes with the ISIS 2'MOE chemistry employed in ISIS-SMNRx and appears to be of higher potency/affinity, but much less defined safety.
Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.